LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
June 23, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 23, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”) announced today that it has received confirmation from The Nasdaq Stock...
Global Cancer Therapies Market Analysis Report 2022-2026: Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
August 05, 2022 06:08 ET
|
Research and Markets
Dublin, Aug. 05, 2022 (GLOBE NEWSWIRE) -- The "Cancer Therapies - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Cancer Therapies Market...
Global RWE Oncology Market Research Report 2022
August 04, 2022 07:23 ET
|
Research and Markets
Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "RWE Oncology Market by Component, Application, End User - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The RWE...
Global Orphan Cancer Drug Market Report 2022-2028
July 12, 2022 06:48 ET
|
Research and Markets
Dublin, July 12, 2022 (GLOBE NEWSWIRE) -- The "Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. ...
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
April 12, 2022 13:53 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
Notable Announces Leadership Team Expansion
April 09, 2020 14:03 ET
|
Notable Labs
SAN FRANCISCO, April 09, 2020 (GLOBE NEWSWIRE) -- Notable, a technology leader redefining cancer treatment through rapid drug development via a clinically validated platform, announced today its...
Notable Named To Fast Company’s Inaugural List Of The 50 Best Workplaces for Innovators
August 05, 2019 10:45 ET
|
Notable Labs
SAN FRANCISCO, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development at a fraction of the...
Notable Announces $40M Series B Round to Fuel Development of Its Drug Discovery Platform for Personalized Oncology
July 16, 2019 07:00 ET
|
Notable Labs
SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development at a fraction of the...
In Personalized Medicine Feasibility Study, Stanford Medical Center, With Partners Notable and Tempus, Able to Make Rapid Personalized Treatment Recommendations for 100 Percent of Blood Cancer Patients
April 15, 2019 13:38 ET
|
Notable Labs
SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with a clinically validated AI platform that rapidly advances cancer drug development at a fraction of...
Oncology Startup Notable Expands Leadership Team With New Chief Medical and Chief Development Officers
February 25, 2019 11:00 ET
|
Notable Labs
FOSTER CITY, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development at a fraction...